Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Limb Girdle Muscular Dystrophy Associated With TRIM32 Variants: A National Cohort Study.

Muscle & nerve·2026
Same author

Does Overall Treatment Time Impact Toxicity and Clinical Outcomes After Magnetic Resonance Imaging-Guided Stereotactic Body Radiotherapy to the Prostate? An evaluation of the Multi-OutcoMe EvaluatioN of radiation Therapy Using the MR-Linac Repository.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same author

Stereotactic Body Radiotherapy for Extracranial Oligometastatic Pancreatobiliary Cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

Eye rubbing, pillow contact, and corneal endothelial cell density.

Journal francais d'ophtalmologie·2025
Same author

A randomized Phase II trial of High Dose-Rate (HDR) and Low Dose-Rate (LDR) brachytherapy as monotherapy in localized prostate cancer: analysis of initial arms of Canadian cancer trials group PR19 (NCT02960087).

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2025
Same author

Tumour-Specific Growth Rate as a Potential Predictor of Outcomes in Oligoprogressive Disease Treated With Stereotactic Body Radiotherapy.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025

Related Experiment Video

Updated: Feb 22, 2026

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.8K

Stereotactic Body Radiotherapy versus Low Dose Rate Brachytherapy for Localised Prostate Cancer: a Cost-Utility

J Helou1, S Torres2, H B Musunuru3

  • 1Department of Radiation Oncology, University of Toronto, Toronto, Canada; Princess Margaret Cancer Centre, Toronto, Canada; Institute of Health Policy, Measurement and Evaluation, University of Toronto, Toronto, Canada.

Clinical Oncology (Royal College of Radiologists (Great Britain))
|September 17, 2017
PubMed
Summary
This summary is machine-generated.

Stereotactic body radiotherapy (SBRT) is a more cost-effective treatment for localized prostate cancer than low dose rate brachytherapy (LDR-BT). SBRT offers better outcomes and lower costs, making it an economically attractive option.

Keywords:
Cost–utilitylow dose rate brachytherapyprostate cancerstereotactic body radiotherapy

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.2K
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

16.3K

Related Experiment Videos

Last Updated: Feb 22, 2026

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.8K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.2K
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

16.3K

Area of Science:

  • Oncology
  • Health Economics
  • Radiation Therapy

Background:

  • Localized prostate cancer (PCa) requires effective treatment strategies.
  • Stereotactic body radiotherapy (SBRT) and low dose rate brachytherapy (LDR-BT) are established treatment options.
  • Cost-utility analysis is crucial for evaluating healthcare interventions.

Observation:

  • A Markov model simulated patient outcomes from a healthcare payer perspective.
  • The model analyzed a 66-year-old man with low-risk PCa over his lifetime.
  • Key health states included recurrence-free, biochemical recurrence, metastasis, and death.

Findings:

  • SBRT was the dominant strategy, yielding more quality-adjusted life years (QALYs) at a lower cost compared to LDR-BT.
  • Results were sensitive to biochemical recurrence (BR) probabilities; LDR-BT became preferred under specific higher BR scenarios for SBRT or lower BR for LDR-BT.
  • When BR was equal for both, LDR-BT showed marginal QALY gains at a significantly higher cost per QALY.

Implications:

  • SBRT presents an economically favorable radiation strategy for localized prostate cancer.
  • Further research with long-term follow-up and high-quality evidence is recommended.
  • These findings can inform clinical decision-making and healthcare resource allocation.